Search Results - "D’Adamo, D. R."

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors by Dickson, M.A., Okuno, S.H., Keohan, M.L., Maki, R.G., D'Adamo, D.R., Akhurst, T.J., Antonescu, C.R., Schwartz, G.K.

“…HSP90 inhibition leads to proteosomal degradation of activated KIT and has in vitro activity against gastrointestinal stromal tumors (GIST). BIIB021 is an oral…”
Get full text

rsc : a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral by D'ADAMO, D. R, NOVICK, S, KAHN, J. M, LEONARDI, P, PELLICER, A

“…A novel oncogene, rsc (rabbit squamous cell carcinoma), has been identified from a DMBA-induced rabbit squamous cell carcinoma using gene transfer and the nude…”
Get full text

Palliative Referrals in Advanced Cancer Patients: Utilizing the Supportive and Palliative Care Indicators Tool and Rothman Index by Chan, Abigail Sy, Rout, Amit, ’Adamo, Christopher R. D., Lev, Irina, Yu, Amy, Miller, Kenneth

“…Background: Timely identification of palliative care needs can reduce hospitalizations and improve quality of life. The Supportive & Palliative Care Indicators…”
Get full text

Subgroup analysis of leiomyosarcoma (LMS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced liposarcoma (LPS) and LMS by Blay, J.-Y., Schoffski, P., Bauer, S., Krarup-Hansen, A., Benson, C., D'Adamo, D.R., Guo, M., Maki, R.

Get full text

Piloted operations at a near-Earth object (NEO) by Landis, Rob R., Abell, Paul A., Korsmeyer, David J., Jones, Thomas D., Adamo, Daniel R.

“…In late 2006, NASA's Constellation Program sponsored a study to examine the feasibility of sending a piloted Orion spacecraft to a near-Earth object. NEOs are…”
Get full text

A Summer Health Program for African-American High School Students in Baltimore, Maryland: Community Partnership for Integrative Health by Pierce, Beverly, Bowden, Brandin, McCullagh, Molly, Diehl, Alica, Chissell, Zachary, Rodriguez, Rebecca, Berman, Brian M., D׳Adamo, Christopher R.

“…Physical inactivity, poor nutrition, and chronic stress threaten the health of African-American youth in urban environments. Conditions often worsen in summer…”
Get full text

A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST) by D'Adamo, D. R., Keohan, M. L., Carvajal, R. D., Hensley, M. L., Hirst, C., Qin, L., Antonescu, C., Lefkowitz, R. A., Schwartz, G. K., Maki, R. G.

“…Abstract only…”
Get full text

Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial by Kindler, H. L., Campbell, N. P., Wroblewski, K., Maki, R. G., D'Adamo, D. R., Chow, W. A., Gandara, D. R., Antonescu, C., Stadler, W. M., Vokes, E. E.

“…Abstract only…”
Get full text

Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST) by Campbell, N. P., Wroblewski, K., Maki, R. G., D'Adamo, D. R., Chow, W. A., Gandara, D. R., Antonescu, C., Stadler, W. M., Vokes, E. E., Kindler, H. L.

“…Abstract only 4 Background: GIST pts who develop resistance to IM and SU have few therapeutic options. SOR inhibits KIT, VEGFR, PDGFR-β, and BRAF kinases. In…”
Get full text

Clinical outcomes in pancreatic adenocarcinoma (PAC) associated with a known BRCA mutation by Lowery, M. A., Stadler, Z. K., Ludwig, E., Salo-Mullen, E., D'Adamo, D. R., Allen, P. J., Kurtz, R. C., Kelsen, D. P., O'Reilly, E. M.

“…Abstract only 268 Background: BRCA1 and -2 germ-line mutations are associated with increased risk of PAC; approximately 5% of all cases of PAC are estimated to…”
Get full text

Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival by Cioffi, A., Italiano, A., Penel, N., Berge, Y., Toulmonde, M., Salas, S., Chevreau, C., Le Cesne, A., Duffaud, F., D'Adamo, D. R., Keohan, M. L., Genebes, C., Antonescu, C., Coindre, J., Bui Nguyen, B., Maki, R. G.

“…Abstract only…”
Get full text

Systemic therapy in clear cell sarcoma by Constantinidou, A., Jones, R. L., Al-Muderis, O., Thway, K., Ashley, S., Scurr, M. R., D'Adamo, D. R., Keohan, M., Maki, R. G., Judson, I. R.

“…Abstract only…”
Get full text

Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF) by Gounder, M. M., Antonescu, C., Hameed, M. R., D'Adamo, D. R., Keohan, M., Singer, S., Brennan, M. F., Ahn, L. S., Maki, R. G.

“…Abstract only…”
Get full text

Direct visualization of circulating sarcoma cells by whole-blood fluorescence in situ hybridization by Morozov, A., Leversha, M., Keohan, M., D'Adamo, D. R., Schwartz, G. K., Meyers, P. A., Maki, R. G., Moore, M. A.

“…Abstract only…”
Get full text

Clinical outcomes in pancreatic adenocarcinoma (PAC) in breast cancer (BC) survivors by Lowery, M. A., Stadler, Z. K., Ludwig Miller, E., D'Adamo, D. R., Salo-Mullen, E., Allen, P., Kurtz, R. C., Kelsen, D. P., O'Reilly, E. M.

“…Abstract only…”
Get full text

Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib by Italiano, A., Cioffi, A., Maki, R. G., Schoffski, P., Rutkowski, P., Le Cesne, A., Duffaud, F., Adenis, A., Isambert, N., Bompas, E., Blay, J., Casali, P. G., Coco, P., D'Adamo, D. R., Keohan, M. L., Toulmonde, M., Antonescu, C., Debiec-Rychter, M., Coindre, J., Bui Nguyen, B.

“…Abstract only…”
Get full text

Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas by D'ADAMO, David R, ANDERSON, Sibyl E, ALBRITTON, Karen, YAMADA, Jennifer, RIEDEL, Elyn, SCHEU, Kelly, SCHWARTZ, Gary K, CHEN, Helen, MAKI, Robert G

“…To evaluate the antitumor activity and tolerability of bevacizumab and doxorubicin in patients with metastatic soft-tissue sarcoma (STS). Patients may have had…”
Get full text

Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060) by D'Adamo, D. R., Keohan, M., Schuetze, S., Undevia, S., Livingston, M., Cooney, M., Kraft, A., Saulle, M., Schwartz, G. K., Maki, R. G.

“…Abstract only 10001 Background: Sorafenib, an oral multi-targeted tyrosine kinase inhibitor, approved for the treatment of renal carcinoma, inhibits tumor cell…”
Get full text

Cardiac toxicity in a phase II study of doxorubicin (DOX) and bevacizumab (BEV) for patients (pts) with metastatic soft-tissue sarcomas (STS) by D'Adamo, D. R., Anderson, S., Albritton, K., Yamada, J., Riedel, E., Scheu, K., Schwartz, G. K., Chen, H., Maki, R. G.

“…Abstract only…”
Get full text

Cardiac toxicity in a phase II study of doxorubicin (DOX) and bevacizumab (BEV) for patients (pts) with metastatic soft-tissue sarcomas (STS) by D'Adamo, D. R., Anderson, S., Albritton, K., Yamada, J., Riedel, E., Scheu, K., Schwartz, G. K., Chen, H., Maki, R. G.

“…Abstract only…”
Get full text